Zilico secures further investment from Deepbridge Capital to advance cancer diagnostics.
The early cancer diagnostic specialist received backing from existing investor Deepbridge Capital alongside leadership changes.
Zilico develops medical diagnostic technology for early cancer detection using its proprietary Electrical Impedance Spectroscopy platform. The firm originated from research at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.
Zilico has secured further investment from existing backer Deepbridge Capital to support its diagnostic technology expansion. The funding follows a separate £1m award from SBRI Healthcare earlier in the year intended for oral cancer device development. Alongside the financial update, the firm announced the appointment of Martin Frost as its new chairman following the departure of Andrew Newell.
From the founder
"I am delighted and look forward to working with Martin. We both share the passion for growing businesses which make a difference in people’s lives. These are exciting times as we forge our plans for Zilico"
Sameer Kothari
Chief Executive at Zilico
Use of funds
- 01Continue product development
- 02Fund research and development